OR03-2 Phase 1, Randomized, Controlled Trial of GFB-024, a Once-Monthly CB1 Inverse Agonist, in Healthy Overweight and Obese Participants and in Participants with Type 2 Diabetes Mellitus

Evidence from nonclinical studies suggests a role of cannabinoid-1 receptor (CB1) in the development of diabetic nephropathy (DN). Kidney CB1 expression is upregulated in podocytes and tubular cells in murine models of obesity and diabetes mellitus (DM). Inhibition by CB1 inverse agonists has been s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilic, Sanela, Dagon, Yossi, Gustafson, Thomas, Johnson, Leslie, Lawler, John, Rudolph-Own, Lori, Gaich, Gregory, Tucker, Edwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Diabetes & Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624947/
http://dx.doi.org/10.1210/jendso/bvac150.723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624947/
http://dx.doi.org/10.1210/jendso/bvac150.723

Ejemplares similares